drug

valbenazine

1 story · latest Jul 30, 2026

Status: FDA approved Apr 2017 · NDA209241, NDA218390
Brands: Ingrezza, Ingrezza Sprinkle
Code: NBI-98854
Trials: 1 registered trial in coverage

Relationships

Developed by Neurocrine Biosciences

Timeline

Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readouts

Jul 30Quarterly updateNeurocrine Biosciences valbenazine

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.